Overlevelsen ved 1, 2 og 3 år var henholdsvis 41, 5%, 21, 1% og 13, 8% for Caelyx sammenlignet med henholdsvis 43, 2%, 17, 2% og 9, 5% for topotecan.
The survival rates at 1, 2 and 3 years were 41.5%, 21.1% and 13.8% respectively on Caelyx, compared to 43.2%, 17.2% and 9.5% on topotecan.